Fig. 4From: Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in JapanTrough serum IFX concentration at Week 14 in patients who did/did not achieve CAI remission. CAI Clinical Activity Index, IFX infliximabBack to article page